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The aim of this study was to measure the sensitivity and specificity of transcutaneous oxygen tension and postocclusive hyperemia
testing using laser Doppler flowmetry in patients with primary Raynaud’s phenomenon. One hundred patients and one hundred
controls were included in the study. Baseline microvascular blood flow and then time to peak flow following occlusion were
measured using laser Doppler flowmetry. Afterwards, the transcutaneous oxygen tension was recorded. The sensitivities of
baseline microvascular blood flow, postocclusive time to peak flow, and transcutaneous oxygen tension were 79%, 79%, and 77%,
respectively.The postocclusive time peak flowhad a superior specificity of 90% and area under the curve of 0.92 as compared to 66%
and 0.80 for baseline microvascular flow and 64% and 0.76 for transcutaneous oxygen tension. Time to postocclusive peak blood
flowmeasured by laserDoppler flowmetry is a highly accurate test for differentiating patients with primary Raynaud’s phenomenon
from healthy controls.
1. Introduction
Raynaud’s phenomenon (RP) is a disorder characterized by
episodic vasospastic attacks of the small blood vessels that
supply the skin of the digits that is precipitated by exposure to
cold or emotional stress. The syndrome takes its name from
Raynaud, who first described the disorder in his 1862 doctoral
thesis [1]. The course of a typical RP attack is an initial
ischemic phasemanifested by blanching or cyanosis, followed
by a rapid reflow of blood marked by digital erythema
(reactive hyperemia).
Vasoconstriction and cutaneous color changes following
exposure to cold stimuli are a normal physiological response
and the pathomechanism which distinguishes RP from this
normal reaction is still unclear [2, 3]. However, evidence
suggests that the mechanism in primary RP may involve
an overexpression or hyperactivity of postsynaptic alpha-2
adrenergic receptors in the smooth muscle of digital vessels
[4, 5].
To date, diagnosis is based on the clinical picture of
reversible changes in color of the digits and discomfort
in response to cold or emotional stress [6, 7]. However,
diagnosis of RP based on observation or patient reports
alone makes it difficult to distinguish patients with primary
RP from those who either are simply sensitive to cold
temperatures or developed secondary RP related to various
conditions, particularly scleroderma, in which RP symptoms
are often observed. Cold challenge tests are generally not used
clinically, may cause patient injury, and have low sensitivity,
specificity, and reproducibility due to individual variation
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in cutaneous blood flow patterns under normal physiologic
conditions [6–8]. A clear systematic approach to objective
diagnosis of RP has yet to be elucidated.
While primary RP is considered a benign condition,
studies have indicated that patients suffering from primary
RP experience a significant decrease in their quality of life
[9, 10]. Furthermore, it is well established that patients with
RP are more likely to develop other rheumatic diseases in the
future. For example, in Buerger’s disease, RP is a common
initial symptom and is present in up to 40% of patients with
the condition [11, 12]. As such, a more accurate and objective
diagnosis of patients with primary RP would allow for more
careful evaluation and management of the patient’s condition
by clinicians.
Much emphasis has been placed on the study of micro-
circulation in patients with RP in the aim of understanding
the vascular underpinnings of the condition, as well as
developing an efficient method for diagnosis. A number
of different techniques have previously been employed to
study skin microcirculation such as capillaroscopy [13, 14],
cold challenge tests [15–17], laser Doppler flowmetry (LDF)
[18–22], thermography [16, 23, 24], and measurement of
transcutaneous oxygen tension [25–27]. However, to date, no
diagnostic test has been universally implemented for aiding
in the diagnosis of primary RP [6].
LDF is a valuable, noninvasive method of analyzing
microcirculatory changes in RP [18–22, 28]. It measures
the flux of blood cells in a designated area, making it well
suited to monitor transient alterations in skin circulation, as
well as determine general perfusion [29–32]. LDF has good
reproducibility, especially under standardized provocations
[33, 34] and, therefore, has been recommended as a diag-
nostic tool in patients with suspected RP [19, 28]. However,
LDF has not been adapted for widespread clinical use and is
viewed by somemedical practitioners as inappropriate due to
difficulties with implementation and to having a questionable
utility [6].
Some of the difficulties with implementation of LDF as
a diagnostic tool are related to its single point of measure
[35]. These include the sensitivity of the probe to tissue
heterogeneity and movement artefacts. Some of the issues
with implementation can be overcome through the use of
dynamic testing, such as postocclusive reactive hyperemia,
with a probe that is, in a fixed position, firmly attached to skin
[35]. Newer laser Doppler techniques, such as laser Doppler
imaging (LDI), which measures flux over an area instead of a
single point, are being explored for the use in patients with
RP and have thus far reported interesting results [36–38].
However, the newer LDI equipment is more expensive and
is not yet readily accessible for many clinicians [35].
Transcutaneous oxygen tension is another noninvasive
method which has demonstrated efficacy in evaluating per-
fusion in patients with RP [27, 39]. Baseline TcPO
2
has been
found to be lower in patients with disturbances in nutritive
skin perfusion, such as in RP [27].
Transcutaneous oxygen tension and LDF measures may
provide more certainty in objectively assessing subjects with
RP and can be an important addition to the currently
available diagnostic paradigms and thus merits further
investigation. The aim of the present study was to assess
the sensitivity and specificity of TcPO
2
and postocclusive
hyperemia measured with LDF in patients with primary RP.
2. Materials and Methods
2.1. Patients. The study sample was composed of 100 patients
(75 women and 25 men) aged 17 to 49 (mean ± SD 24.97 ±
6.37) with a diagnosis of primary RP, as defined by LeRoy
and Medsger criteria [40] and 100 controls aged 19 to 27
(mean ± SD 23.12 ± 2.38) with the same proportion of
men and women as the study sample. All participants had
their titers of antinuclear antibodies and rheumatoid factor
tested and underwent an evaluation of their thyroid function.
For inclusion in the study, all the tested parameters had
to be within normal limits and not reveal any autoim-
mune or thyroid dysfunctions. The exclusion criteria for the
study included a history of smoking (within the past six
months), diabetes, hypertension, or any regular medication
use, including oral anticontraceptives, hormone replacement
therapy, and nicotine replacement therapy. No participant
had any trophic changes to the fingers, and participants were
asked not to remove any periungual tissues two weeks prior
to the study. All participants were asked to refrain from
consumption of any caffeinated or alcoholic beverages prior
to the examination. No participant was wearing nail varnish
during the testing. Furthermore, capillaroscopic tests were
performed to ensure that no morphological abnormalities
were present in the tested areas, as such findings would be
suggestive of secondary RP [41]. Investigators conducting
further tests (LDF and TcPO
2
measurements) were blind as
to whether the subject belonged to the RP patient group or to
the control group.
2.2. Tests. Each test was carried out in a room with an
increased sound absorption at a temperature of 21–23 degrees
Celsius. Testing was preceded by a 15-minute resting period,
during which the patient sat in a comfortable position. Finger
skin temperature was measured using ELLAB ctd 85 system
(Copenhagen, Denmark) with the ELLA PRC A probe,
calibrated per the manufacturer’s guidelines. The probe was
positioned on lateral aspect of the distal phalanx and was sta-
bilized using the pressure cuff of the occlusion test (Figure 1).
Baseline microvascular blood flow was then measured using
the LDF apparatus for a duration of 5 minutes. Following
the baseline assessment, LDF postocclusion hyperemia time
to peak blood flow and TcPO
2
values were measured. For
the purposes of this paper, baseline microvascular blood flow
measured in arbitrary perfusion units (PU) will be referred
to as bMBF, and the postocclusion time to peak blood flow
measured in seconds will be referred to as tpMBF.
2.3. LDF. LDF measurements were made using the Peri-
flux4001 Master apparatus (Perimed AB, Jarfalla, Sweden)
calibrated per the manufacturer’s guidelines with the Capy
Flow software package to register and analyze the results.
The apparatus was equipped with a probe of standard fiber
separation (0.25mm) and a 780 nm wavelength laser with
a measuring depth of 0.5–1.0mm. The probe was stabilized
BioMed Research International 3
(a)
(b)
(c)
(d)
Figure 1: Position of the probes and measuring equipment on the
hand: (a) TcPO
2
probe, (b) pressure cuff, (c) thermometer, and (d)
LDF probe and probe holder.
on the dorsal aspect of distal phalanx of the right middle
finger at the level of the nail. The degree of adhesion of the
probe to the skin was controlled by the flowmeter sensor.
LDFmeasurements are expressed in arbitrary perfusion units
(PU); thus the bMBF values were recorded in such units.
Following baseline blood flowmeasurement, a small pressure
cuff was mounted at the level of the proximal phalanx
of the tested finger and inflated to 200mmHg to induce
occlusion for a period of one minute, starting from the
moment the biological zero flow signal is registered by the
LDF machinery. The pressure was then released in the cuff
within one second and the time to peak blood flow return
was measured (tpMBF). Peak blood flow was considered
as the highest recorded blood flow value assessed in PU
after release of the pressure cuff. The LDF was measured
for a period of 5 minutes after occlusion. A cuff inflation
pressure of 200mmHg and an occlusion duration of one
minute were chosen for the study based on recommendations
of Bollinger and Fagrell, who described a one-minute arterial
occlusion to be optimal for assessment of postocclusive
reactive hyperemia in finger nailfold capillaries [42].
2.4. TcPO
2
. Transcutaneous oxygen tension measurements
were made using a calibrated TCO2M (Novametrix Medical
Systems Inc., Wallingford, USA) apparatus at an electrode
temperature of 44∘C, 20 minutes after LDF testing of the
tpMBF. The patient’s skin was cleaned with alcohol and
electrodes were positioned on the dorsum of the hand in
the second intermetacarpal space. Transcutaneous oxygen
tension levels were recorded after stabilization, over a period
of 5 minutes.
2.5. Statistical Analysis. Statistical analysis was conducted
using the SPSS Statistics 17.0 software package (SPSS Inc.,
Chicago, IL, USA) and MedCalc ver. 13.1.2.0 for Windows
(MedCalc Software Inc., Marierke, Belgium). All data was
tested for normality using the Shapiro-Wilks tests. The
independent 𝑡-test was conducted on normally distributed
data, while nonparametric testing using the Mann–Whitney
U test was employed on data that did not meet the criteria of
normality. A 𝑝 value < 0.05 was considered significant.
Receiver operating characteristic curve analysis was com-
pleted using the MedCalc software to evaluate diagnostic
values of the tests. All diagnostic cut-off points were deter-
mined by computing Youden’s index [43], a single statistic
for assessing diagnostic performance, for each of the three
tests. Based on the cut-off points, the sensitivity, specificity,
positive predictive value, and negative predictive values were
computed. For each ROC curve, the AUC was calculated.
The AUC describes the chance of a randomly selected person
with RP testing positive for the condition using one of the
aforementioned tests, as compared to a randomly selected
patient who does not have RP (an AUC of 1 = a perfect test
where all patients are with RP test positive for the disease
using the selected test; 0.5 = noninformative test).
2.6. Ethics. The protocol of this study was approved by the
Jagiellonian University Medical College Bioethics Commit-
tee. Written, informed consent was given by each participant
prior to inclusion into the study. This study has been con-
ducted in accordance with the 1963 Helsinki Declaration and
its later amendments.
3. Results
Baseline microvascular blood flow and tpMBF data were
not normally distributed; thus nonparametric analysis using
the Mann–Whitney U test was employed, while the TcPO
2
data was normally distributed allowing for an independent
𝑡-test to be conducted. Descriptive statistics for the study
population can be found in Table 1. There was no significant
difference in the mean age between controls (23.12 ± 2.38
years) and patients with RP (24.97 ± 6.37 years; 𝑝 = 0.43).
Furthermore, no sex differences were found for any of the
measures (all 𝑝 values > 0.05). The mean duration of disease
for patients with primary RP was 6.60 (±4.85) years.
The mean finger skin temperature of patients with RP
after a 15-minute resting period in a temperature controlled
room was 26.47 (±2.50) degrees Celsius, while the mean
temperature for controls was 27.35 (±2.34; 𝑝 = 0.021) degrees
Celsius. No significant correlation was found between mean
finger skin temperature and any other variable for both the
patient group and the control group.
Compared with controls, patients with RP had a lower
bMBF (15.2 ± 6.45 versus 24.7 ± 9.36PU; 𝑈 = 1971; 𝑝 <
0.001), higher tpMBF values (16.4 ± 10.7 versus 4.87 ± 1.75
seconds; 𝑈 = 787; 𝑝 < 0.001), and lower TcPO
2
(56.2 ± 9.73
versus 66.7 ± 10.8mmHg; 𝑡 = −7.24; 𝑝 < 0.001; Figure 2). No
significant difference in peak blood flow was found between
the study group and the control group (𝑡 = 1.97; 𝑝 = 0.54).
The mean peak blood flow for the study group was 84.1 ±
23.2 PU and for the control group was 91.2 ± 28.2 PU.
3.1. ROC Analysis. Cut-off values to diagnose primary RP for
each diagnostic test were obtained by computing Youden’s
index. The calculated cut-offs used for bMBF, tpMBF,
and TcPO
2
were ≤19.3 PU, >7.2 seconds, and ≤62.6mmHg,
respectively. Based on these cut-offs, the sensitivity, speci-
ficity, PPV, and NPV of each diagnostic test were computed
(Table 2). Receiver operating characteristic curves gener-
ated for each diagnostic test can be found in Figure 3,
along with the corresponding sensitivity and specificity
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Table 1: Descriptive values of the study population.
(a) Patient’s diagnosed with Raynaud’s syndrome
𝑁 Minimum Maximum Mean Standard error Standard deviation
bMBF (PU) 100 4.30 33.2 15.2 0.645 6.45
tpMBF (seconds) 100 3.00 65.0 16.4 1.070 10.7
TcPO
2
(mmHg) 100 34.2 84.2 56.2 0.972 9.73
(b) Controls
𝑁 Minimum Maximum Mean Standard error Standard deviation
bMBF (PU) 100 10.20 46.10 24.7 0.936 9.36
tpBF (seconds) 100 1.60 46.10 4.87 0.175 1.75
TcPO
2
(mmHg) 100 45.90 91.10 66.7 1.080 10.8
TcPO2
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Figure 2: Difference in values obtained for bMBF, tpMBF, and TcPO
2
between controls and patients with primary RP. bMBF: baseline
microvascular blood flow; tpMBF: postocclusive time to peak microvascular blood flow; TcPO
2
: transcutaneous oxygen tension.
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Table 2: Sensitivity and specificity of the diagnostic tests.
Cut-off value Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI
bMBF ≤19.3 PU 79% 69.7–86.5 66% 55.8–75.2 69.9% 60.6–78.2 75.9% 65.5–84.4
TcPO
2
≤62.6mmHg 77% 67.5–84.8 64% 53.8–73.4 68.1% 58.8–76.6 73.6% 63.0–82.5
tpMBF >7.2 seconds 79% 69.7–86.5 90% 82.4–95.1 88.8% 80.3–94.5 81.1% 72.6–87.9
PPV: positive predictive value; NPV: negative predictive value; 95% CI: 95% confidence interval.
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Figure 3: ROC curves of the predictive power of basal microvascular blood flow, LDFmeasures of time tomax blood flow following vascular
occlusion, and TcPO
2
on the presence or absence of Raynaud’s syndrome. bMBF: baseline microvascular blood flow; tpMBF: postocclusive
time to peak microvascular blood flow; TcPO
2
: transcutaneous oxygen tension.
plot versus criterion values which can be found in Sup-
plement 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/9645705.
The sensitivities of bMBF (79.0%; 95% CI: 69.7–86.5),
TcPO
2
(77.0%; 95% CI: 67.5–84.8), and tpMBF (79.0%; 95%
CI: 69.7–86.5) were all similar. However, tpMBF was found to
have a significantly greater specificity (90.0%; 95% CI: 82.4–
95.1) as compared to bMBF (66.0%; 95% CI: 55.8–75.2) and
TcPO
2
(64.0%; 95% CI: 53.8–73.4), indicating that tpMBF is
the superior test at ruling in the diagnosis of primary RP.
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Table 3: Area under the curve (AUC) for the three diagnostic techniques examined.
AUC SE 95% CI 𝑝
bMBF 0.8029 0.0301 0.7439–0.8619 <0.0001
tpMBF 0.9212 0.0190 0.8840–0.9583 <0.0001
TcPO
2
0.7589 0.0334 0.6935–0.8213 <0.0001
SE: standard error; CI: confidence interval.
This is also reflected in the greater positive likelihood ratio
of tpMBF (7.9; 95% CI: 4.4–14.3) as compared to bMBF (2.32;
95% CI: 1.7–3.1) and TcPO
2
(2.14; 95% CI: 1.6–2.8). Negative
likelihood ratios of tpMBF (0.23; 95% CI: 0.2–0.3), bMBF
(0.32; 95% CI: 0.2–0.5), and TcPO
2
(0.36; 95% CI: 0.2–0.5)
were not significantly different.
The AUC values for the ROC curves are shown in
Table 3. Pairwise comparison of the AUCs for the three
diagnostic tests revealed that the AUC for the tpMBF plot was
significantly different than both bMBF (𝑧 = 3.33;𝑝 = 0.0009)
and TcPO
2
(𝑧 = 4.12; 𝑝 < 0.0001) measures. AUCs for
bMBF and TcPO
2
were not found to be significantly different
(𝑝 > 0.05). The AUC of tpMBF (0.92; 95% CI: 0.88–0.95)
was greater than that of bMBF (0.80; 95% CI: 0.74–0.86)
and TcPO
2
(0.76; 95% CI: 0.69–0.82), indicating the superior
diagnostic accuracy of tpMBF for diagnosing primary RP as
compared to the other measures. Additional data regarding
the ROC curve analysis can be found in Supplement 2.
4. Discussion
Blood flow is controlled by a complex network of vasocon-
strictive and vasodilative processes mediated by neural input
and the release of vasoactive substances. In RP, the vasospas-
tic attacks likely reflect changes in the balance of such physi-
ological mechanisms [4, 44–46]. In the present investigation,
bMBF and TcPO
2
measures were significantly reduced in
patients with primary RP as compared to controls. A previous
study by Wollersheim et al. [22] also examined bMBF in
patients with RP versus controls and found similar significant
differences. The authors further investigated bMBF between
patients with primary versus secondary RP but found no
significant difference between these two groups [22].
Interestingly, though bMBF was significantly different
between the groups in our study, peak blood flow after
occlusion, measured in arbitrary perfusion units, was not
significantly different between the study and control groups.
However, while both patients with primary RP and controls
can reach peak blood flows of similar magnitude, the time by
which this occurs differentiates patients from controls.
In the posthyperemic time to peak blood flow measured
by LDF, patients with RP took over 3 times longer to reach
peak blood flow. This test had a greater specificity (90.0%)
and a stronger positive likelihood ratio (7.9) as compared to
bMBF (66.0%, 2.32) and TcPO
2
(64.0%, 2.14) measures. As
such, while sensitives were not significantly different among
the three modalities, the higher specificity and positive
likelihood ratio of tpMBF, as compared to bMBF and TcPO
2
,
demonstrate tpMBF’s superior ability to rule-in the diagnosis
of primary RP.
Receiver operating characteristic curve analysis for the
postocclusive time to peak blood flow (tpMBF) demonstrated
that this diagnostic modality is highly accurate, with an
AUC of 0.92. This indicates that a randomly selected person
with RP is very likely to test positive (approximately 92%)
for the condition using the LDF postocclusion hyperemia
measurement of time to peak blood flow. While less accurate
than tpMBF, bMBF andTcPO
2
also hadAUCvalues that were
fairly high (0.80 and 0.76, resp.) and there was no significant
difference between these two measures.
The advantage of postocclusion hyperemia measures in
differentiating between cases and controls may stem from the
provocation of a physiologic induced vasodilator response.
Although the exact mechanism is unknown, reactive hyper-
emia is thought to occur due to the build-up of vasodilator
metabolites such as endothelium-derived nitric oxide follow-
ing vascular occlusion, which decreases vascular resistance
leading to increased blood flow to the ischemic tissue [47,
48]. In patients with primary RP, it has been found that the
dilator responses, induced by iontophoresis of the NO donor
nitroprusside, are reduced in the digital vessels suggesting
that the dilator action of NO is depressed in RP [45, 46].This
decrease in NO dilator function may in part be explained
by the inactivation of NO by oxidative stress, stemming
from repeated vasospastic episodes, followed by ischemia-
reperfusion [44].
Additionally, increased production of the potent
endothelial derived vasoconstrictor endothelin-1, as well as
a lack of downregulation of endothelin receptors, has been
reported in patients with RP and may also help explain the
observed prolonged time to postocclusive peak blood flow in
RP patients as compared to controls [49, 50]. However, other
studies have found no difference in resting endothelin levels
between patients with RP and controls [51].
Furthermore, it has been suggested that the cyclooxyge-
nase (COX) pathway produces vasoconstrictive metabolites
such as prostaglandinH
2
, whichmay limit finger vasodilation
in RP patients [52]. Aspirin, a blocker of COX activity, was
found to enhance vasodilation evoked by the iontophoresis
of acetylcholine in RP [52]. These studies provide evidence
to suggest that an imbalance between vasoconstriction and
vasodilation is likely to be at least partially involved in the
mechanism in RP.
The LDF measured time to peak blood flow following
occlusion was best able to capture the differences between
controls and cases, likely by forcing the ischemic digit to
evoke the compensatory vasodilator response which may be
limited in RP patients. Vasodilator mechanisms responsible
for maintaining blood flow can affect both the bMBF and
TcPO
2
levels, but are more active under periods of deviation
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from homeostasis. This may have made the tpMBF measure
more accurate at capturing the vascular response changes
between controls and RP patients.
The lack of a standardized diagnostic test for RP limits
the ability of clinicians to accurately diagnose the condition
and instead forces them to rely solely on patient’s history
and clinical observations. Recently, a panel of international
experts formulating a consensus on criteria for the diagnosis
of RP scored LDF to be an inappropriate test for being both
difficult to implement clinically and having a questionable
utility [6]. However, we suggest that using LDF to measure
the postocclusive time to peak blood flow may be a quick
and easy to use noninvasive diagnostic test to increase the
accuracy of the diagnosis of suspected primaryRP in a patient
in whom the clinical picture and laboratory results do not
suggest an underlying secondary cause of the symptoms.
With its high sensitivity and specificity, tpMBF may aid in
objectively assessing patients with suspected primary RP, and
future studies should further examine the clinical efficacy of
this diagnostic modality.
However, to be universally applied as a diagnostic test in
RP, the test should have a high specificity for discriminating
between primary and secondary RP [15]. In a similar study
byWollersheim et al. [22], the measurement of postocclusive
recovery time by LDF was able to accurately discriminate
between primary and secondary RP.However, further clinical
studies are needed to assess the diagnostic value and efficacy
of tpMBF to distinguish between primary and secondary RP,
which was not measured in this study.
Some of the difficulties with implementation of LDF as
a diagnostic tool are related to its single point of measure
[35]. These include the sensitivity of the probe to tissue
heterogeneity and movement artefacts. Some of the issues
with implementation can be overcome through the use of
dynamic testing, such as postocclusive reactive hyperemia,
with a probe that is in a fixed position, firmly attached to skin
[35]. Newer laser Doppler techniques, such as laser Doppler
imaging (LDI), which measures flux over an area instead of a
single point, are being explored for the use in patients with
RP and have thus far reported interesting results [36–38].
However, the newer LDI equipment is more expensive and
is not yet readily accessible for many clinicians [35].
In our study, significant differences were found in the
mean finger skin temperature between patient’s with RP and
controls after a 15-minute resting period in a temperature
controlled room. It was interesting to find that despite a
slightly lower mean finger skin temperature, controls had a
higher bMBF. However, it is important to note that tpMBF as
measured by LDF is independent of skin temperature, and,
moreover, there were no correlations between skin tempera-
ture and any other variable for either RP patients or controls.
The present study did not find any difference in the basal
microvascular blood flow between men and women, which
is in contrast to previous data that found basal cutaneous
blood flow in the hands and fingers of young women to
be roughly half of that seen in young men [53]. However,
there was a predominance of females and a small sample of
males, thus limiting the ability to detect such differences.This
study also focused on single testing sessions which mimics
clinical settings but limits the ability to detect changes in the
results between sessions. Multiple testing sessions could help
identify any variability in the results that could hinder the
diagnostic value. Lastly, it would be worthwhile to identify
the dominant hand and look at blood flow across both hands,
as well as across all digits, to see how uniform the reported
changes are.
Though newer integrating LDF probes decrease spatial
variability and likely improve accuracy as compared to a
single point LDF as used in this study, they are more
expensive, with few clinics having access to such equipment
to data. However, as costs decrease and integrating probes
become more accessible to clinicians, these probes may be an
improved alternative to single point LDF. In particular, LDI,
due its ability to measure flux over an area, has the potential
to improve accuracy over a single point LDF. Early studies
applying this modality in the diagnosis of RP have shown
promising results [36–38]. As such, future studies should
assess the diagnostic utility of LDI inmeasuring postocclusive
hyperemia.
5. Conclusions
Time to peak blood flow, as measured by LDF, is a quick,
easy to use diagnostic tool that shows high sensitivity and
specificity for differentiating patients with RP from healthy
controls. As such, tpMBFmay be used to objectively diagnose
patients with primary RP, after exclusion of potential sec-
ondary causes of the condition. The efficacy of this diagnostic
modality may lie in its ability to capture the deficiency in
the occlusion induced vasodilator responses of the implicated
vasculature.
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